Status:
COMPLETED
Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure
Lead Sponsor:
Charite University, Berlin, Germany
Conditions:
Kidney Failure, Chronic
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
Patients with end-stage renal failure have a markedly higher mortality because of cardiovascular events in comparison with the normal population. Disorders in the calcium metabolism, such as calcifica...
Detailed Description
Trial protocol for ADAM Study 1.1 General Data: 1. Title of the Study: Influence of Amlodipine on the Mortality of Patients with End-Stage Renal Failure (abbreviated title: ADAM \[Amlodipine and Dia...
Eligibility Criteria
Inclusion
- End-stage renal disease
- Hemodialysis
- Hypertension
- Written informed consent
Exclusion
- Hypotension of less than 90 mmHg systolic
- High-grade aortic stenosis
- Heart failure of NYHA stage III and IV
- Acute myocardial infarction (within the last 4 weeks)
- Acute heart failure
- Known allergy to the medicament amlodipine or other constituents of the medicament
- Severe disorders of liver function
- Pregnancy and breast-feeding
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2006
Estimated Enrollment :
356 Patients enrolled
Trial Details
Trial ID
NCT00124969
Start Date
January 1 2002
End Date
October 1 2006
Last Update
May 9 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charite Campus Benjamin Franklin
Berlin, Germany, 12200